中文名称: | TR-14035 | ||||
---|---|---|---|---|---|
英文名称: | TR-14035 | ||||
CAS No: | 232271-19-1 | 分子式: | C24H21Cl2NO5 | 分子量: | 474.33 |
CAS No: | 232271-19-1 | ||||
分子式: | C24H21Cl2NO5 | ||||
分子量: | 474.33 |
基本信息
产品编号:T10796 |
|||||
产品名称:TR-14035 |
|||||
CAS: |
232271-19-1 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
六个月 |
||
分子量 |
474.33 |
-20℃ |
一个月 |
||
化学名: |
|
||||
Solubility (25°C) |
体外 |
DMSO |
95mg/mL (200.28mM) |
||
Ethanol |
20mg/mL (42.16mM) |
||||
Water |
Insoluble |
||||
体内(现配现用) |
|
|
|||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.1082mL |
10.5412mL |
21.0824mL |
5mM |
0.4216mL |
2.1082mL |
4.2165mL |
10mM |
0.2108mL |
1.0541mL |
2.1082mL |
50mM |
0.0422mL |
0.2108mL |
0.4216mL |
生物活性
产品描述 |
一种 α4β7/α4β1 整合素双重抑制剂,对 α4β7 和 α4β1 作用的 IC50 值分别为 7nM和 87nM。TR-14035 可用于炎症和自体免疫疾病的研究。 |
|
靶点/IC50 |
α4β7 |
α4β1 |
7nM |
87nM |
|
体外研究 |
TR14035 blocks adhesion of RPMI-8866 cells to MAdCAM-Ig by 100% at 1μM, with an approximate IC50 of 0.01μM. |
|
体内研究 |
TR-14035 (3mg/kg; i.g.) produces a significant decrease of the airways hyper-responsiveness to 5-hydroxytryptamine (5-HT) in an experimental model of allergic asthma in Brown Norway rats.TR-14035 exhibits moderate oral bioavailability (rat 17.1%, dog 13.2%) and Cmax (rat 0.18, dog 0.10μg eq./mL) following oral administration (rat 10 and dog 10mg/kg).TR-14035 exhibits terminal elimination half-lives (rat 0.28h and, dog 0.81h) due to high plasma clearance (3865 and 1664mL/h/kg respectively) following intravenous administration (rat 3mg/kg and dog 3mg/kg). |
|
Animal Model: |
Male Brown Norway rats (250-300g) |
|
Dosage: |
3mg/kg |
|
Administration: |
Oral gavage, 1 h before and 3h after antigen challenge |
|
Result: |
Suppressed antigen-induced airway hyper-responsiveness and inflammation. |
|
|
||
Animal Model: |
Male Sprague-Dawley rats (250-320g) |
|
Dosage: |
3mg/ kg for i.v.; 10mg/kg for oral (Pharmacokinetic Analysis) |
|
Administration: |
Intravenous injection and oral administration |
|
Result: |
Oral bioavailability (17.1%), Cmax (0.18μg eq./mL), T1/2 (0.28h). |
|
|
||
Animal Model: |
Male beagle dogs |
|
Dosage: |
3 mg/kg for i.v.; 10mg/kg for oral (Pharmacokinetic Analysis) |
|
Administration: |
Intravenous administration and oral administration |
|
Result: |
Oral bioavailability (13.2%), Cmax (0.10μg eq./mL), T1/2 (0.81h). |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )